Zenrelia (ilunocitinib) is indicated for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. Allergic dermatitis can make your dog very uncomfortable. Symptoms like excessive itching, scratching, and biting aren’t only disruptive to you and your pet, but they can also cause more severe problems over time, including hair loss and skin infection. The active ingredient, ilunocitinib, reduces the inflammatory response in your dog’s skin caused by allergies. Fast relief for your best friend is also a relief for you. Spend more time doing the things you love, like cuddling and playing, and less time managing your dog’s allergy symptoms. Dosage: 0.27 to 0.36 mg/lb. body weight, administered orally, once daily, with or without food.

WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination (see Warnings and Target Animal Safety).